由于证据不足,林业发展局从重量损失药物中清除了自杀风险警告。 FDA removes suicide risk warnings from weight-loss drugs due to insufficient evidence.

美国食品及药品管理局已要求流行减重药品制造商从标签上删除自杀风险警告, The U.S. Food and Drug Administration has asked manufacturers of popular weight-loss medications to remove suicide risk warnings from their labels, citing insufficient evidence to support the link. 这项行动是在对临床试验数据和安全报告进行审查之后采取的,尽管该机构强调病人安全仍然是优先事项。 The move follows a review of clinical trial data and safety reports, though the agency emphasized that patient safety remains a priority. 此项决定可能会影响硫酸盐和tirzepatide等药物,后者广泛用于体重管理。 The decision may affect drugs like semaglutide and tirzepatide, widely used for weight management.